Scientific Research presented
in the 1st Virtual Sexology and
Hispanoamerican Sexual Education
Congress (February -2001)
Dr. Eduardo A. Gomez de Diego „
1998 Andrology Services ,Andromedical
Clinic, Madrid (Spain)
1. Introduction:
When the human tissues are
submitted to a force of
traction, they react by
increasing in size.
The principle of traction is
applied in modern medicine, for
the generation of new tissue to
cover burn wounds or areas of
hair loss ( placing a tissular
expander underneath the normal
skin ) or for the lengthening of
bones.
In other cultures this principle
is applied to lengthen different
parts of the body like the
Giraffe Women of the Paduang
tribe in Birmania ; or the
lengthening of the lips in
certain African tribes of Africa
that use wood to create
traction; and in India where
they hang stones on the penis of
men as a form of penitence with
the resulting enlargement of the
organ.
Based on this principle of
external traction the
SizeGenetics® was designed . It
is able to exhort a gradual
traction force of 600 to 1500
grams.
The device consists of a plastic
ring, where the penis is
introduced and from where 2
dynamic metalic rods that
originate the traction. In the
superior part there is a plastic
support where a silicone band
holds the glans in place.
Based on our clinical experience
the traction device yields the
following results:
An increase in the length of the
penis in erection and
flaccidity.
An increase in the perimeter of
the penis in erection and
flaccidity.
This results will be analyzed
statistically to be verified and
quantified
2. Materials and Methods
Number of patients: 37 patients,
ages between 22 and 60 years of
age. These men proceed from
different cities in Spain.
Selection of patients: patients
included were healthy men with
normal erection capabilities and
without penile surgeries.
Patients with penile or other
diseases where excluded from the
studies.
Traction device: The
SizeGenetics®, German penile
traction device.
Traction Force: 600 gr during
1st month, 900 gr during 2nd
month, 1100 gr durante 3th and
4th mes, and 1200 gr during 5th
y 6th month.
Usage period: 10 hours a day,
during every day of the month
for a period of 3-6 months.
-
3. Results
3.1.- INCREASE IN LENGTH IN
ERECTION:

The average increase in the
length of the penis in erection
by month is of 0.4726 cm. The
standard deviation is of 0.1329
cm. The confidential interval of
95% is of [0.4283 ; 0.5169]
which indicates a minimal gain
in the population of 0.4283
cm/month.

Regression line is:
DL erec = - 0.327 + 0.562 x t
This calculation will allow us
to estimate the increase in
length of the penis in erection,
based on the months of use of
the device. There is a 57.7%
variance in the increment in
longitude, which is explained by
the variance in the duration of
treatment ( R2= 0.577 ). The
other 42.3% is due to other
differences innate to each
individual and not relative to
the duration of the treatment

3.2.- INCREMENT IN LENGTH IN THE
FLACCID STATE
The increment in length in the
flaccid state is relative to the
time of usage of the device.
Such an increment is linear as
shown in the graph. The longer
the device is used, the greater
the increase in length. The
coefficient of the linear
correlation between the time of
usage and the increment in
longitude in the flaccid state
is of 0.725 ( p=0.000 ).

The average monthly increment in
longitude of the penis in the
flaccid state is 0.4834 cm and
the typical deviation is 0.1983
cm. The confidence interval of
95% is of [0.4173 ; 0.5495] and
indicates a minimum increase in
the population of 0.4173
cm/month.

Regression line is:
DL flac = - 1.300 + 0.840 x t
This calculation allows us to
estimate the increment in
longitude in the flaccid state
based on the months in which the
device is used. There is a 52.5%
variance in the increment in
longitud which is explained by
the variance of the duration of
treatment ( R2= 0.525 ). The
other 47.5% is due to other
differences innates to the
individual and not relative to
the duration of the treatment.

3.3.- VARIABILITY:
The variability in the increment
in longitude in erection is
different from that of
flaccidity, being the difference
in variance significant ( p=
0.003 ) which indicates a
greater dispersion of the
increases in length during
flaccidity than in erection.
--------------------------------------------------------------------------------
3.4.- THE INCREMENT IN LONGITUDE
DOES NOT DEPEND ON THE AGE:
A very interesting result was
that the increment in longitude
does not depend on the age of
the patient, since the
coefficient of the linear
correlation is not significant (
r=0.008, p=0.961). In other
words, the age of the patient
does not effect the increment in
longitude.


3.7.- LONGITUDE INCREASE IN
ERECTION STATE DEPENDING ON USE:
Dividing the population studied
in four sub groups depending on
the usage time of the
SizeGenetics®. we obtain the
following results.
Three months usage:
The median longitude increment
in erection state was 1.4118,
obtaining a median growth of
10.5580% over the initial
longitude. The confidence
interval of 95% of the studied
population was ( 1.1522; 1.6713)
which shows a median minimal
growth of 1.1522 cm in three
months.
Four months usage:
The median longitude increment
in erection state was 1.8462,
obtaining a median growth of
14.1113% over the initial
longitude. The confidence
interval of 95% of the studied
population was(1.5809; 2.1114)
which shows a median minimal
growth of 1.5809 cm in four
months

Five months usage:
The median longitude increment
in erection state was 2.2750,
obtaining a median growth of
16.6303% over the initial
longitude. The confidence
interval of 95% of the
population studied was (1.7656;
2.7844) which shows a median
minimal growth of 1.7656 cm in
four months.
Six months usage:
The median longitude increment
in erection state was 3.3333,
obtaining a median growth of
27.5% over the initial
longitude. The confidential
interval of 95% of the
population studied was (2.8162;
3.8504) which shows a median
minimal growth of 2.8162 cm in
six months.
The samples corresponding to
five and six months are very
small which makes small
intervals and less reliable.

3.8.- DISTRIBUTION:
Although the variables
considered in the population are
not normal, the median samples,
have normal distribution since
the amount of the sample is
greater than 20.
--------------------------------------------------------------------------------
3.9.- ABBREVIATIONS:
Inc-Long-Erec Longitude
increment in erection state
DL erec Change in Longitude
increment in erection state
I.L.ERT Longitude increment in
erection as a function of the
time variable
I.L.FLAC Longitude increment in
flaccid state
DL flac Change in Longitude
increment in flaccid state
I.L.FLT Longitude increment in
flaccid state in function of
time
Inc-Long-Erec Longitude
increment in erection state
% I Long-Erec Longitude
increment percentage in erection
state.
4. Conclusions
The use of the German traction
device ( SizeGenetics® ) will
increase the length of the
penis, both in the erectile and
flaccid state.
The increase in length, both in
and flaccidity, is directly
proportional to the time of use.
The increase in length both in
erection and flaccidity, does
not depend on the natural size
of the patient.
The average growth in length of
the penis in cm/month in 95% of
the patients was between 0.4283
and 0.5163 in erection, and
between 0.4173 and 0.5495 in
flaccidity.
The increments of change in
length of the penis in erection
are more uniform than those in
flaccidity which tend to be more
disparate .
The increment of change in the
length of the penis in erection
is not relative to the age of
the patient.
The use of the penile traction
device will increase the
perimeter of the penis, both in
erection and flaccidity.
The average growth in perimeter
in cm/month in 95% of the
patients was between 0.6111 and
1.0200 in erection, and between
0.6386 and 1.0425 in flaccidity.
Treatment was 3-6 months
duration.
-
5. Anex
PATIENT RESULTS (Using the
SizeGenetics®):
| Nombre
|
Edad |
Inicio |
L-Erec1 |
L-Flac1 |
P-Erec1 |
P-Flac1 |
Meses |
L-Erec2 |
L-Flac2 |
P-Erec2 |
P-Flac2 |
| LAA |
60 |
15.1.98
|
12.0 |
8.0 |
12.0 |
10.0 |
3.0 |
13.5 |
9.0 |
13.5 |
10.5
|
| EAG |
37 |
30.1.98
|
14.5 |
8.0 |
12.0 |
8.5 |
4.0 |
16.5 |
9.5 |
13.0 |
10.5
|
| VA |
27 |
26.11.97
|
16.3 |
10.4 |
13.9 |
10.1 |
3.0 |
17.8 |
12.5 |
14.5 |
11.5
|
| EAA |
46 |
15.3.98
|
14.5 |
10.5 |
12.0 |
10.0 |
6.0 |
17.6 |
15.7 |
13.2 |
11.2
|
| JBV |
25 |
27.3.98
|
15.0 |
8.0 |
13.0 |
9.0 |
3.0 |
16.6 |
9.5 |
13.3 |
10.5
|
| ABB |
39 |
29.6.98
|
14.0 |
11.0 |
13.0 |
11.0 |
3.0 |
15.5 |
12.5 |
14.0 |
12.0
|
| CBG |
37 |
19.1.98
|
12.5 |
6.0 |
12.0 |
9.0 |
4.0 |
14.0 |
8.8 |
12.5 |
9.4
|
| JBL |
25 |
7.5.98
|
13.7 |
9.0 |
11.5 |
10.0 |
4.0 |
16.3 |
11.5 |
13.5 |
12.0
|
| JCB |
27 |
19.11.97
|
13.0 |
8.0 |
14.5 |
12.0 |
6.0 |
16.4 |
11.1 |
14.2 |
12.2
|
| JJCA |
33 |
1.6.98
|
10.5 |
4.9 |
11.0 |
9.5 |
3.0 |
12.0 |
5.5 |
11.5 |
9.5
|
| JCA |
32 |
4.2.98
|
14.0 |
10.0 |
10.0 |
9.0 |
4.0 |
15.9 |
12.0 |
12.2 |
10.5
|
| ODV |
25 |
4.3.98
|
16.5 |
9.5 |
13.0 |
9.7 |
3.0 |
18.0 |
11.0 |
13.3 |
10.0
|
| PDS |
22 |
10.6.98
|
14.4 |
8.3 |
11.0 |
7.8 |
3.0 |
15.8 |
9.0 |
11.6 |
8.3
|
| AGM |
41 |
26.11.98
|
13.0 |
9.0 |
11.0 |
10.0 |
4.0 |
15.0 |
9.5 |
11.0 |
10.0
|
| MGF |
32 |
29.9.97
|
12.5 |
5.5 |
12.5 |
10.0 |
4.0 |
14.5 |
8.0 |
13.0 |
10.0
|
| AHM |
44 |
5.3.98
|
11.5 |
8.0 |
13.0 |
12.0 |
3.0 |
13.0 |
9.5 |
14.0 |
12.0
|
| AAMP |
37 |
12.3.98
|
12.7 |
7.0 |
10.5 |
7.5 |
3.0 |
14.0 |
9.0 |
11.0 |
9.0
|
| JLMO |
34 |
30.1.98
|
14.8 |
11.0 |
11.0 |
9.3 |
4.0 |
15.8 |
11.0 |
12.7 |
9.3
|
| JAMV |
41 |
28.7.97
|
17.0 |
10.0 |
14.0 |
12.5 |
5.0 |
19.6 |
12.3 |
15.0 |
13.5
|
| FOR |
8% |
9.11.97
|
12.5 |
7.0 |
10.0 |
9.0 |
5.0 |
14.5 |
11.0 |
11.0 |
10.5
|
| ROM |
28 |
12.11.97
|
16.0 |
8.5 |
13.0 |
9.0 |
5.0 |
18.0 |
12.5 |
13.5 |
10.5
|
| JPC |
33 |
16.1.98
|
13.7 |
7.2 |
12.3 |
10.1 |
3.0 |
16.7 |
8.7 |
13.1 |
10.9
|
| JAPG |
29 |
4.11.97
|
10.0 |
8.0 |
12.0 |
10.0 |
6.0 |
13.5 |
11.5 |
13.0 |
11.0
|
| FPR |
8% |
20.3.98
|
10.5 |
7.0 |
12.0 |
10.0 |
3.0 |
11.3 |
7.3 |
12.7 |
10.0
|
| JPF |
42 |
23.3.98
|
13.0 |
7.0 |
13.0 |
10.0 |
3.0 |
14.5 |
8.5 |
13.0 |
10.5
|
| AJRF |
26 |
28.11.97
|
14.0 |
9.0 |
13.0 |
9.0 |
4.0 |
16.0 |
10.7 |
13.0 |
10.0
|
| ARR |
58 |
7.10.97
|
11.0 |
7.0 |
11.0 |
9.0 |
3.0 |
12.0 |
8.0 |
12.0 |
10.0
|
| RRG |
25 |
25.11.97
|
14.5 |
11.0 |
11.0 |
10.0 |
3.0 |
15.0 |
12.4 |
11.7 |
10.8
|
| CSM |
35 |
24.2.98
|
15.0 |
9.0 |
11.0 |
9.0 |
3.0 |
16.5 |
11.0 |
12.0 |
10.0
|
| ASE |
35 |
20.3.98
|
12.5 |
7.5 |
11.5 |
9.0 |
4.0 |
14.5 |
9.5 |
12.5 |
10.5
|
| ASPA |
42 |
7.11.97
|
14.0 |
7.5 |
12.0 |
9.0 |
4.0 |
16.0 |
9.5 |
13.0 |
10.5
|
| SSF |
27 |
15.8.97
|
14.5 |
7.0 |
14.5 |
8.0 |
3.0 |
15.9 |
8.0 |
15.0 |
8.7
|
| ISB |
22 |
23.9.97
|
11.5 |
7.5 |
11.0 |
9.5 |
4.0 |
13.5 |
10.2 |
11.3 |
10.3
|
| FT |
53 |
19.11.97
|
14.5 |
10.0 |
13.0 |
10.0 |
3.0 |
16.0 |
11.5 |
13.5 |
10.5
|
| EVC |
24 |
29.12.97
|
11.0 |
7.0 |
11.5 |
9.0 |
5.0 |
13.5 |
9.0 |
12.5 |
10.5
|
| PV |
33 |
8.10.97
|
12.0 |
8.5 |
15.5 |
13.0 |
4.0 |
13.0 |
9.5 |
16.0 |
13.0
|
| JSVS |
32 |
24.1.98
|
12.0 |
6.0 |
10.5 |
9.0 |
4.0 |
14.0 |
8.5 |
12.5 |
9.5
|
L-Erec1 = Length in Erection
initial
L-Flac1 = Length in Flaccidity
inicial
P-Erec1 = Perimeter in Erection
initial
P-Flac1 = Perimeter in
Flaccidity inicial
L-Erec2 = Length in Erection
final
L-Flac2 = Length in Flaccidity
final
P-Erec2 = Perimeter in Erection
final
P-Flac2 = Perimeter in
Flaccidity final
|